Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis

PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 19, 2023

Primary Completion Date

June 17, 2024

Study Completion Date

June 20, 2024

Conditions

Anemia

Interventions

DRUG

SAL-0951 tablets

initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

DRUG

rHuEPO injection

Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks

Trial Locations (1)

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY